Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MPLT

MapLight Therapeutics Inc

Oct 31 • 04:00PM ET

16.92

-1.45 -7.89 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-	Insider Own	44.78%	Shs Outstand	41.43M	Perf Week	-
Market Cap	701.00M	Forward P/E	-	EPS next Y	-	Insider Trans	52.59%	Shs Float	22.88M	Perf Month	-
Enterprise Value	955.56M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-7.74%
Book/sh	-5.92	P/C	11.59	EPS next 5Y	-	ROE	-	52W High	20.86 -18.87%	Perf Year	-
Cash/sh	1.46	P/FCF	-	EPS past 3/5Y	-60.77% -	ROIC	-	52W Low	15.00 12.80%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.89	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	4.89	EPS Q/Q	-149.10%	SMA20	-2.68%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	-2.68%	Rel Volume	0.27	Prev Close	18.37
Employees	-	LT Debt/Eq	0.08	Earnings	-	SMA200	-2.68%	Avg Volume	1.20M	Price	16.92
IPO	Oct 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	319,985	Change	-7.89%

Oct-29-25 09:06AM	MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-26-25 05:30PM	MapLight Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	Oct 28 '25	Buy	17.00	952,941	16,199,997	3,686,622	Oct 30 04:31 PM
Catalyst4, Inc.	10% Owner	Oct 28 '25	Buy	17.00	5,441,176	92,499,992	19,697,464	Oct 29 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MPLT

MapLight Therapeutics Inc

Upgrade your FINVIZ experience